Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin plus chemoradiotherapy for advanced nasopharyngeal carcinoma
ChiCTR2000028905Phase 4Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of metformin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
metformin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2000028905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028905.